PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data - Slideshow

PepGen released topline Phase II FREEDOM2 study results for its lowest-dose MAD cohort, demonstrating favorable safety profiles and splicing efficacy in March 2026. The data highlighted significant improvements in vHOT (vectorized human oligonucleotide therapy) metrics, suggesting potential therapeutic viability for targeted genetic disorders. Early findings showed no severe adverse events, reinforcing the treatment’s tolerability at the tested dose level, a critical milestone for advancing clinical trials. Preliminary splicing corrections aligned with preclinical expectations, validating PepGen’s platform for RNA-modulating therapies in neuromuscular diseases. The results position PepGen to accelerate enrollment for higher-dose cohorts, aiming to expand efficacy and safety validation in broader patient populations.